POU5F1 and neoplasm: These findings suggest that ΔCEA holds potential as a clinical biomarker for determining the undifferentiated tumor phenotype, advanced clinical stage, and poor therapeutic response in RC patients with positive expression of the OCT4 CSCs marker.